Purported modified ACTH/Semax peptide; chemical identity not established
Adamax
aka N-acetyl-adamantyl Semax amide (claimed identity; not independently verified)
Grade note: Even the preclinical basis is thin.
User reports
approximate — combined from two independent Reddit reads
Men 45–60
0 men aged 45–60
No reports in this group yet.
All men
1 man
small sample · n = 1Outcome mixed 1 of 1
Benefits focus / cognition 1 of 1
Side effects headache 1 of 1 · insomnia 1 of 1
Everyone
4 people
small sample · n = 4Outcome positive 3 of 4 · mixed 1 of 4 · unclear 1 of 4
Benefits mood / anxiety 3 of 4 · focus / cognition 2 of 4
Side effects headache 1 of 4 · insomnia 1 of 4
User reports are anecdata, not evidence: self-selected, unverified, often combined with other compounds.
In their words
“within a few hours there was definitely a significant boost in clarity and overall cognitive function”
“headaches were happening a lot more frequently and I found It was harder to fall asleep.”
“I feel like I’m actually appreciating things again. Music hits harder, small things make me happier”
“Basically, Adamax was a godsend while wrapping up my master's, along with phenylpiracetam when caffeine wasn't enough.”
“ADAMAX - I think I’m finally starting to feel things again. Has anyone else experienced this? I've been emotionally numb/blunted”
Read summaries and method notes
Read 1. No men aged 45–60 were identified; the only explicitly male reporter in the counted sample was 21. That reporter described noticeable cognitive clarity within hours and better memory after about a week, with more headaches and difficulty falling asleep. A second reporter described a return of emotional range and greater enjoyment after starting Adamax, although they explicitly acknowledged uncertainty about causality. These reports are specific to Adamax rather than generic Semax; however, the usable Reddit corpus was exceptionally thin and one seed post had been removed. The sample is too small to characterize age-specific response or frequency of adverse effects.
Read 2. No man aged 45–60 or stated man. Four self-reporters from 12 threads: 3 positive, 1 unclear — mood/anxiety relief (including emotional blunting lifting) and cumulative cognitive gains. No side effects logged; commentary warns against bedtime dosing and that many grey-market sprays are not authentic Adamax. Reliability low.
Note 1. Extremely sparse Adamax-specific data. Generic Semax reports were excluded. One counted user later combined Adamax with Selank.
Note 2. Very small sample. Several seed threads were about standard Semax and were excluded.
Each read counted people independently. Overlap between the two reads is estimated from shared threads and removed; counts are approximate. How we count.
Summary
Purported analogue of Semax, an ACTH-derived peptide. The claimed N-acetyl/adamantyl structure, enhanced metabolic stability and brain penetration were not independently verified. Marketed for focus, working memory, mental fatigue, mood/anxiety and ADHD-type complaints; Adamax-specific human efficacy trials were not found in the searches performed. Regulatory submission
Proposed mechanism
Proposed by analogy with the parent compound, not demonstrated for Adamax itself:
- BDNF/NGF and monoamine effects have not been verified for Adamax; the cited Semax rat experiment concerns another molecule. Semax study
- Enhanced CNS penetration, stronger effects at lower doses, resistance to aminopeptidases and longer duration remain unverified hypotheses. They cannot explain reported crashes causally.
Reported routes: intranasal spray/drops and occasional SubQ use are anecdotal descriptions, not validated clinical routes.
Safety
- Identity, human pharmacokinetics and dose-response unverified
- No reliable adverse-event incidence, interaction or long-term safety data found
- Parent-compound safety cannot establish derivative safety
From labels, regulators and trials. No signal in small studies ≠ safe.
Legal status
US FDANot approved
Approval and compound-specific 503A category not found. Not on July 23–24, 2026 PCAC agenda or October HHS Appendix A; Semax policy does not cover a purported derivative. Source
checked 2026-11-13WADA 2026Likely prohibited (S0)
S0 prohibition inferred for an unapproved pharmacological substance; not named. Source
checked 2026-11-13Re-check pending: HHS interim policy is a draft; re-check after the comment period.
Evidence D nootropic
D stands as the rubric's floor. There is no human trial and no primary animal study either - the grade should carry a note that even the preclinical basis is missing.
Human trials · 0
No human trials found for the marketed use.
Dose ranges
Reported ranges from labels and studies, with context. Not a recommendation.
No data.
Editorial ratings EDITORIAL
Editors’ judgement, 0–5. Opinion, not data; separate from grade and user score.
Sources
- hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf
- wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf
- ema.europa.eu/en/medicines
- pubmed.ncbi.nlm.nih.gov/?term=Adamax+peptide
- pubmed.ncbi.nlm.nih.gov/?term=adamax
- pubmed.ncbi.nlm.nih.gov/30577777/
- pubmed.ncbi.nlm.nih.gov/16996037/
- clinicaltrials.gov/search?term=Adamax
- fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-5
- fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-c
- ema.europa.eu/en/search?search_api_fulltext=Adamax
Reddit threads read · 8
2 further sources on commercial or non-primary hosts not listed.
Research checked 2026-11-13.